SEC Form 4 · accession 0000950138-19-000003
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Matthew K Harbaugh
Officer — President, Spec Gen
Period of report
Jan 2, 2019
Accepted (ET)
Jan 4, 2019 · 5:45 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary SharesF1 | Jan 2, 2019 | F | 341 | $16.59 | D | 108,484 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 704 shares acquired between June 30, 2018 and December 31, 2018 under the Mallinckrodt employee stock purchase plan.